Medications for gastroesophageal reflux disease
Pro Research Analysisby 
Searched over 200M research papers
Proton Pump Inhibitors (PPIs) as First-Line Medications for GERD
Proton pump inhibitors (PPIs) are the mainstay and first-choice treatment for gastroesophageal reflux disease (GERD). They are highly effective in reducing stomach acid, alleviating symptoms, healing esophagitis, and preventing complications in most patients 1234. However, up to 20–40% of patients may experience inadequate symptom relief or persistent symptoms despite PPI therapy 1257. For these patients, strategies such as optimizing adherence, increasing the dose, switching to a different PPI, or considering alternative medications are recommended 27.
Potassium-Competitive Acid Blockers (P-CABs) and Their Role
Potassium-competitive acid blockers (P-CABs), such as vonoprazan, are a newer class of acid-suppressive drugs that provide rapid, potent, and long-lasting acid suppression. P-CABs have shown promising results, especially in patients who do not respond well to PPIs, and may be particularly useful for on-demand or noncontinuous therapy due to their quick onset of action 25810. Studies suggest that P-CABs can be used as primary or add-on therapy to improve symptom control in refractory GERD cases 5810.
Adjunctive and Alternative Medications for GERD
For patients who do not respond to PPIs or P-CABs, several adjunctive and alternative medications may be considered:
- Histamine-2 Receptor Antagonists (H2RAs): These drugs can be used, especially at night, to control breakthrough symptoms, but are generally less effective than PPIs for severe GERD 37.
- Prokinetics: These medications aim to improve esophageal motility and gastric emptying. However, clinical trial results are inconsistent, and their use is generally reserved for specific cases 147.
- Reflux Inhibitors (e.g., Baclofen): Baclofen, a GABA agonist, can reduce reflux episodes and improve symptoms, particularly in patients with non-acid reflux or those with concurrent conditions like obesity or alcohol use disorder. Side effects are generally mild but more common with long-term use 19.
- Antidepressants and Neuromodulators: These may help patients with non-erosive reflux disease (NERD) and visceral hypersensitivity, but more research is needed to confirm their effectiveness 126.
- Mucosal Protective Agents: These drugs or medical devices reinforce the esophageal lining and can be used as add-on therapy in refractory cases 1457.
Maintenance and Noncontinuous Therapy Approaches
Long-term maintenance therapy is often required for patients with severe or recurrent GERD. Both continuous and on-demand (noncontinuous) therapy strategies are used. On-demand therapy, especially with P-CABs, is appealing for patients with mild or episodic symptoms, as it reduces medication exposure and cost while maintaining symptom control 210. Sequential maintenance therapy, starting with daily medication and transitioning to on-demand use, can improve patient satisfaction and minimize drug exposure .
Considerations for Medication Selection and Risk Factors
The choice of medication should be tailored to the individual, considering the severity of symptoms, response to previous treatments, and potential side effects. Some drugs, such as certain anti-inflammatory agents, hormone therapies, and calcium channel blockers, can worsen GERD symptoms or contribute to its development by affecting esophageal motility or mucosal integrity . Objective testing may be necessary for patients who do not respond to standard therapies to confirm the diagnosis and guide further treatment 27.
Conclusion
PPIs remain the cornerstone of GERD treatment, but a significant number of patients require alternative or adjunctive therapies. P-CABs, prokinetics, reflux inhibitors, neuromodulators, and mucosal protective agents offer additional options, especially for those with refractory symptoms. Individualized treatment plans and consideration of noncontinuous therapy approaches can help optimize symptom control and improve quality of life for GERD patients 1245+3 MORE.
Sources and full results
Most relevant research papers on this topic
New and Future Drug Development for Gastroesophageal Reflux Disease
New and future drugs for gastroesophageal reflux disease (GERD) focus on potent histamine type 2 receptor antagonists, extended release PPI's, PPI combination, potassium-competitive acid blockers, transient lower esophageal sphincter relaxation reducers, pro
Potassium-competitive acid blockers and gastroesophageal reflux disease
Potassium-competitive acid blockers (P-CABs) provide quick, powerful, and extended acid suppression for gastroesophageal reflux disease, offering a valuable treatment option for unmet needs and enhancing the effectiveness of proton pump inhibitors.
Which drugs are risk factors for the development of gastroesophageal reflux disease?
Drugs like nitrates, calcium channel blockers, and benzodiazepines can increase the risk of developing or exacerbating gastroesophageal reflux disease.
DOI
A Review of Medical Therapy for PPI Non-responsive Gastroesophageal Reflux Disease
Switching to a CYP2C19 independent PPI or using adjunctive medications may help improve acid suppression in patients with PPI nonresponsive GERD.
DOI